Molbio Diagnostics coming with IPO to raise up to Rs 950.03 crore

Molbio Diagnostics

• Molbio Diagnostics is coming out with a 100% book building; initial public offering (IPO) of 1,17,72,311 shares of face value Rs 1 each in a price band Rs 768-807 per equity share. 
• Not more than 50% of the issue will be allocated to Qualified Institutional Buyers (QIBs), including 5% to the mutual funds. Further, not less than 15% of the issue will be available for the non-institutional bidders and the remaining 35% for the retail investors.
• The issue will open for subscription on August 10, 2026 and will close on August 12, 2026.
• The shares will be listed on BSE as well as NSE.
• The face value of the share is Rs 1 and is priced 768 times of its face value on the lower side and 807 times on the higher side.
• Book running lead managers to the issue are Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors.
• Compliance officer for the issue is Darshan Raghunath Karekar. 

Profile of the company

Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. It has developed its ‘Truenat’ platform, which is a novel POC polymerase chain reaction (PCR) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour. Truenat is patented in more than 100 countries for the diagnosis of multiple infectious and non-communicable diseases. It offers molecular testing for 30 diseases, including tuberculosis (TB), COVID, Hepatitis B and C, Human immunodeficiency virus (HIV), and Human Papillomavirus (HPV) with 43 assays. 

It operates in an oligopolistic market with high entry barriers, evidenced by the fact that its platform underwent 13 years of R&D to obtain Indian Council of Medical Research (ICMR) certification and its ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of the only two rapid molecular tests in the world, which has been endorsed by the World Health Organization (WHO) for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology. It also provides devices, enabling radiology, digital pathology and breast health screening, through its Subsidiaries, Prognosys and OptraScan and collaboration partner - UE Lifesciences. Further, it is focussed towards building a pipeline of additional products and platforms that are currently at various stages of development.

Its ‘Truenat’ platform, equipped with fully automated, user-friendly features such as portability, simple workflow and rapid sample-to-result turnaround time, is designed to perform a wide array of tests swiftly and efficiently with high sensitivity and specificity compared to conventional diagnostic methods. These features address the challenges faced by underserved populations worldwide, including limited access to diagnostic facilities, cost-effective diagnostic solutions, timely detection and treatment of diseases and electricity-dependent laboratory infrastructure. It aims to establish a new standard of healthcare by ensuring accessibility to advanced testing technology for underserved populations globally through portable and cost-effective testing solutions that deliver accurate results, ensuring essential medical care.

Proceed is being used for: 

• Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by its wholly-owned subsidiary, Bigtec and connected office space for the company, subsidiaries and associate.
• Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit.
• General corporate purposes.

Industry overview

The diagnostics industry is increasingly recognised as the cornerstone of India’s expanding healthcare sector, propelled by the essential need for accurate diagnosis as the first step in effective healthcare delivery. This market encompasses a wide range of tests and procedures, classified broadly as in vitro diagnosis (pathological tests), which involve tests performed on samples taken from the human body, and in vivo tests (radiology), which involve tests and procedures within the living body to visualise or measure internal body functions and structures. The Indian diagnostics market has shown significant growth between Fiscal 2021 to 2026 and is projected to continue this robust trend through Fiscal 2031. 

The diagnostics market was valued at Rs 725.8 billion ($10.31 billion) in Fiscal 2021 and grew to Rs 1,354.2 billion ($15.3 billion) in Fiscal 2026, at a CAGR of 13.3% for the said period. The in vitro diagnostics market (IVD) accounts for 56.1% of the diagnostics market, valued at Rs 760.5 billion ($8.6 billion) in Fiscal 2026. Looking ahead, the diagnostics market is projected to grow at a CAGR of 11.7% from Fiscal 2026 to 2031 and is estimated to reach a market value of Rs 2,356.5 billion ($26.6 billion) in Fiscal 2031. This growth trajectory will be propelled by the growing incidence of chronic illnesses, increasing demand for preventive screenings, rising geriatric population, and government healthcare access programs.

Meanwhile, India has become the diabetes capital of the world and a hotbed for major infectious diseases such as TB. It is evident that India holds significant market potential in both Endocrinology and Infectious disease (based on the number of tests performed). The infectious point-of-care testing (POCT) market is estimated to have a market potential of Rs 89.7 billion ($1.0 billion), closely followed by endocrinology diseases with a market potential of Rs 90.5 billion ($1.0 billion) in Fiscal 2026. These markets are projected to reach Rs 237.8 billion ($2.7 billion) and Rs 173.1 billion ($1.9 billion) respectively, by Fiscal 2031, due to the high prevalence of lifestyle diseases and the growing incidence of infectious diseases in the region. Enhanced healthcare infrastructure, increased investments in diagnostic technologies, and growing awareness about early disease detection are expected to drive the infectious disease market further, resulting in a higher CAGR of 21.5% between Fiscal 2026 to 2031P.

Pros and strengths 

Well placed to address unmet demand in a large and growing molecular diagnostic market: Its ‘Truenat’ platform enables screening and diagnosis for 30 infectious and non-communicable diseases, including TB, COVID, Hepatitis B and C, HIV, and HPV. Over the years, it has established its expertise in providing testing solutions to the last mile, offering accurate and rapid solutions to improve disease diagnosis and pandemic preparedness. For example, in 2020, it received its first major order of 1,512 devices from the Government of India under the TB Programme, which were then quickly repurposed for COVID 19 testing using its test kits. This highlights its platform’s capability to diagnose multiple diseases and demonstrated its ability to respond to health crisis. Once COVID-19 testing declined, the public health programs for TB resumed their normal course. Its ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of the only two rapid molecular tests in the world, which has been endorsed by WHO for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology.

Innovative, R&D focused business: It has strong in-house R&D capabilities with a track record of developing innovative diagnostic products. It undertakes R&D through its wholly-owned subsidiary, Bigtec, to design and develop diagnostic platforms that address gaps in clinical need and can be effectively deployed in POC settings. Its commitment to R&D is evident through the launch of an initial version of its novel platform, which underwent extensive R&D work for over 13 years, and obtained ICMR certification. Its R&D capabilities allow it to develop tests swiftly and efficiently. Further, its ‘Truenat’ Nipah virus test chip is the first in India to receive emergency use authorisation from the Drug Controller General of India for diagnosing the Nipah virus. Its emphasis on R&D has helped it earn recognition and accolades over the years. For instance, ICMR recognized ‘Truenat’ MTB and ‘Truenat’ MTB-Rif as POC detection tests in 2017. In addition, it received the ‘Product of the Year’ award in 2020 from BioSpectrum.

Developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform: It has developed and commercialized a novel portable POC molecular diagnostics platform, which uses PCR technology to enable accurate and rapid molecular diagnostics. Its ‘Truenat’ platform comprises two portable instruments - the Trueprep universal nucleic acid extraction device, which performs fully automated sample preparation; and the Truelab analyzer, which conducts real-time PCR. These tests are conducted using its disease specific ‘Truenat’ test kits. These test kits are ready-to-use, room temperature stable, single-use consumables that are pre-loaded with all reagents required to conduct a real-time PCR test on the Truelab analyzers.

Scalable business model with strong entry barriers, high proportion of recurring revenues and a growing suite of tests: Its ‘Truenat’ platform is a closed system, comprising Trueprep extraction and Truelab analyzer devices, which are designed to work exclusively with its range of ‘Truenat’ test kits. These disease-specific ‘Truenat’ test kits ensure recurring demand and use of its platform. Trueprep devices utilize a cartridge-based extraction and purification protocol of nucleic acids from multiple specimen types, while Truelab engages in real-time PCR using Truenat test kits for the detection of infectious and non-communicable diseases. Once its devices are installed, multiple diseases can be tested for, using its range of ‘Truenat’ test kits. This flexibility enables it to grow the suite of tests it offers, accommodating a wide range of infectious and non-communicable diseases. This enhances the value proposition to healthcare providers by allowing them to conduct tests for various diseases using the same device. It operates in an oligopolistic market with high entry barriers, evidenced by the fact that its platform underwent 13 years of R&D to obtain ICMR certification and its ‘Truenat’ platform for diagnosing TB is the only one by an Indian company and one of the only two rapid molecular tests in the world, which has been endorsed by the WHO for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology.

Risks and concerns

Business dependence on government, international aid agencies: It derives a portion of its revenues from the sale of its products to the Indian central and state governments, and international aid agencies for their public healthcare programs. Its revenue from such government and international aid agencies was 84.56%, 87.83% and 91.60% of its revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. Any unfavourable policy changes by these agencies or a decrease in funding for public healthcare programs may impact the sale of its products and adversely affect its business, financial condition, results of operations and cash flows. Further, its revenue from the top 10 customers was 83.26%, 83.62% and 78.54% of its revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. The loss of any of these customers or a decline in demand for its products from them could also have an adverse effect on its business, financial condition, results of operations and cash flows.

Significant revenue from sale of TB diagnostic test kits: It derives a portion of its revenues from the sale of diagnostic test kits for tuberculosis (TB). Its revenue from the sale of test kits for TB was 70.20%, 69.11% and 62.40% of its revenue from contracts with customers - sale of products - finished goods in the Fiscals 2026, 2025 and 2024, respectively. Any decline in the demand for diagnostic test kits for TB, whether due to fluctuations in the number of cases, the adoption of alternative diagnostic methods, advancements in diagnostic technologies, changes in government policies concerning TB testing or the government or international aid agencies’ programs run to eradicate TB, or supply chain disruptions such as raw material shortages or logistical challenges causing delays in product availability, could adversely affect its business, financial condition, operational results, and cash flows.

Liability risks associated with product accuracy: The marketing, sale, and use of its products could lead to the filing of product liability claims if someone alleges that its products provided inaccurate or incomplete information regarding their infections, or otherwise failed to perform as designed. It may also be subject to liability for errors in, a misunderstanding of, or inappropriate reliance upon the information, it provides in the ordinary course of its business activities. Any product liability claims or regulatory actions could be costly and time-consuming to defend and may adversely affect its reputation, brand image, business, results of operations and financial condition. If successful, product liability claims may require it to pay substantial damages. While it maintains product liability insurance which primarily covers its diagnostic tests for COVID-19, Beta CoV, SARS CoV-2, H1N1, Influenza A/B, H3N2/H1N1, Nipah, MTB, it cannot assure that any future product liability claims will be adequately covered, and claims may exceed the coverage limits of its policy. As it increases its sales, it may be unable to maintain sufficient product liability insurance coverage on commercially reasonable terms, or at all. A product liability claim, with or without merit, could result in negative publicity and adversely affect the marketability of its products and its reputation.

Dependence on technological advancements and innovation: The molecular diagnostic industry is competitive and characterised by extensive R&D and rapid technological changes. Its success will depend in part on its ability to develop or respond to technological advances and emerging standards and practices on a cost effective and timely basis. It cannot assure that it will be able to successfully make timely and cost-effective enhancements and additions to its technological infrastructure, keep up with technological improvements in order to meet its customers’ needs or that the technology developed by others will not render its products less competitive or attractive. The cost of implementing new technologies and R&D initiatives and upgrading its manufacturing units and R&D infrastructure could be time-consuming and costly. Its failure to successfully adopt such technologies in a cost effective and a timely manner could increase its costs and lead to it being less competitive in terms of its prices or quality of products it sells. Further, implementation of new or upgraded technology may not be cost effective, which may adversely affect its business, results of operations, financial condition and cash flows.

Outlook

Molbio Diagnostics and its subsidiaries and its associates are mainly engaged in the business of manufacturing chip based diagnostic devices, chips and reagents, X-ray equipment's, single / dual detector solutions, developing diagnostic devices, performing tests in the bio-sensing domain, digital pathology, etc. It has bolstered its capabilities and expanded its offerings through strategic acquisitions and collaborations with various organizations. It has acquired 65.47% of the equity share capital of Prognosys to bolster its capabilities in radiology. Prognosys helped it enter into digital imaging solutions, including radiology products such as ultraportable X-ray systems, mobile digital X-ray systems, floor-mounted and ceiling-suspended X-ray systems and C-arm systems, all under the brand ‘ProRad’ and a digital health platform under the brand name ‘ProDigi’. On the concern side, it depends on a few suppliers for the supply of some of its raw materials. Its purchase of raw materials from top 10 suppliers accounted for 58.52%, 58.21% and 58.52% of purchases of raw materials and components consumed in Fiscal 2026, 2025 and 2024, respectively. Any disruption in the supply or increase in the prices of raw materials could adversely affect its business, financial condition, results of operations and cash flows.

The issue has been offering 1,17,72,311 shares in a price band of Rs 768-807 per equity share. The aggregate size of the offer is around Rs 904.11 crore to Rs 950.03 crore based on lower and upper price band respectively. Minimum application is to be made for 18 shares and in multiples thereon, thereafter. On performance front, its total income increased by 41.56% to Rs 14,551.70 million for Fiscal 2026 from Rs 10,279.36 million for Fiscal 2025. Its profit increased by 18.45% to Rs 1,641.40 million for Fiscal 2026 from Rs 1,385.79 million for Fiscal 2025.

Meanwhile, it intends to leverage its R&D capabilities to develop new POC platforms using advanced multiplex PCR technologies. These platforms will specifically target critical diagnostic needs in immunochemistry, hematology, histopathology, antimicrobial resistance detection, and biochemistry to address a wide range of other communicable and non-communicable diseases. In addition, it will evaluate inorganic growth opportunities, in keeping with its strategy to grow and develop its market share or to add new product categories. It may consider opportunities for inorganic growth, such as through mergers and acquisitions, if, among other things, they consolidate its market position in existing business verticals, achieve operating leverage in key markets by unlocking potential efficiency and synergy benefits, strengthen and expand its product portfolio and enhance its depth of experience, knowledge-base and know how.